BIIB

Biogen Stock Price

273.97
4.53 (1.68%)
Upgrade to Real-Time
Regular Market
273.97
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Biogen Inc BIIB NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
4.53 1.68% 273.97 15:23:39
Open Price Low Price High Price Close Price Prev Close
271.79 271.00 277.025 269.44
Bid Price Ask Price Spread News
273.97 274.14 0.17 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
14,214 592,372 $ 274.30 $ 162,490,323 1,309,771 223.25 - 374.99
Last Trade Time Type Quantity Stock Price Currency
15:23:49 6 $ 274.05 USD

Biogen Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 42.16B 153.88M 152.99M $ 14.38B $ 5.03B 31.46 8.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Biogen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BIIB Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week276.75282.43267.665271.181,001,124-2.78-1.0%
1 Month248.48282.60238.40259.711,170,76425.4910.26%
3 Months253.64363.92223.25267.831,741,19420.338.02%
6 Months282.68363.92223.25272.401,401,803-8.71-3.08%
1 Year278.14374.99223.25288.021,630,473-4.17-1.5%
3 Years358.00388.67215.775283.371,660,561-84.03-23.47%
5 Years269.46388.67215.775284.071,600,1804.511.67%

Biogen Description

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.


Your Recent History
NASDAQ
BIIB
Biogen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.